Drug Trial Radar · NCT03713632
Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS)
Last checked: Nov 20, 2026Latest source record: Oct 9, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
545
Actual
Start
Feb 25, 2019
Primary completion
Sep 23, 2021
Study completion Jul 19, 2022
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Oct 22, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study was to demonstrate superiority of secukinumab at Week 16, based on Hidradenitis Suppurativa Clinical Response (HiSCR) rates versus placebo, along with the maintenance of efficacy of secukinumab at Week 52 in subjects with moderate to severe HS. Moreover, this study assessed the safety and tolerability of secukinumab.
Conditions
- Hidradenitis Suppurativa
Interventions
SecukinumabDrug
Secukinumab 300mg every 2 or every 4 weeks
PlaceboDrug
Placebo 300mg every 2 or every 4 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Hidradenitis Suppurativa Clinical Response (HiSCR50)Time frame: 16 weeks
Locations
108 sites in 32 countries. Site status is shown where the registry gives one.
Novartis Investigative Site
San Diego, California
Novartis Investigative Site
Whittier, California
Novartis Investigative Site
Coral Gables, Florida
Novartis Investigative Site
Tampa, Florida
Novartis Investigative Site
Sandy Springs, Georgia
Novartis Investigative Site
Indianapolis, Indiana
Novartis Investigative Site
Boston, Massachusetts
Novartis Investigative Site
St Louis, Missouri
Novartis Investigative Site
St Louis, Missouri
Novartis Investigative Site
Omaha, Nebraska
Novartis Investigative Site
New York, New York
Novartis Investigative Site
Portland, Oregon
Novartis Investigative Site
Bellaire, Texas
Novartis Investigative Site
Pflugerville, Texas
Novartis Investigative Site
Norfolk, Virginia
Novartis Investigative Site
Capital Federal, Argentina
Novartis Investigative Site
CABA, Buenos Aires, Argentina
Novartis Investigative Site
Rosario, Santa Fe Province, Argentina
Novartis Investigative Site
Ghent, Belgium
Novartis Investigative Site
Liège, Belgium
Novartis Investigative Site
Pleven, Bulgaria
Novartis Investigative Site
Sofia, Bulgaria
Novartis Investigative Site
Barrie, Ontario, Canada
Novartis Investigative Site
Richmond Hill, Ontario, Canada
Novartis Investigative Site
Drummondville, Quebec, Canada
Novartis Investigative Site
Saint-Jérôme, Quebec, Canada
Novartis Investigative Site
Bogotá, Colombia
Novartis Investigative Site
Barranquilla, Atlántico, Colombia
Novartis Investigative Site
Zagreb, HRV, Croatia
Novartis Investigative Site
Jihlava, Czechia
Novartis Investigative Site
Ústí nad Labem, Czech Republic, Czechia
Novartis Investigative Site
Aarhus, Denmark
Novartis Investigative Site
Copenhagen NV, Denmark
Novartis Investigative Site
Antony, France
Novartis Investigative Site
Martigues, France
Novartis Investigative Site
Nice, France
Novartis Investigative Site
Reims, France
Novartis Investigative Site
Rouen, France
Novartis Investigative Site
Saint-Etienne, France
Novartis Investigative Site
Saint-Mandé, France
Showing 40 of 108 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.